bioMérieux – Business Review for the nine months ended September 30, 2016

• 10.3% organic sales growth for the first nine months of 2016, powered by the Americas and Asia-Pacific regions:
  • Sales reached €1,512 million
  • Up 7.1% as reported
• All strategic lines contributed to the dynamic performance
• FilmArray®: 480bps-contribution to consolidated organic growth for the first nine months of 2016

Alexandre Mérieux, Chief Executive Officer, said: "bioMérieux confirmed its strong sales dynamic over the third quarter and continues to enhance its portfolio of innovative solutions for its customers. Given this favorable environment and as announced upon publication of its half-year results, bioMérieux should exceed its annual 8% organic sales growth target."

Sales

Consolidated sales came in at €1,512 million for the nine months ended September 30, 2016, up 10.3% like-for-like from €1,412 million for the same period one year earlier, and up 7.1% as reported. Reported sales growth reflected a €32 million negative currency effect, as well as the change in scope mainly resulting from the deconsolidation of bioTheranostics as of January 1, 2016.

Organic growth remained strong in third-quarter 2016, as sales gained 9.1% on the prior-year period. FilmArray® sales soared 78%, spurred by accelerated growth of instrument sales. Business in emerging countries, which accounted for around 25% of the Group's sales in the third quarter, advanced 10.4% on the year-earlier period.

Download the Full Press Release: